220 related articles for article (PubMed ID: 31200359)
1. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Gbolahan O; Hashemi-Sadraei N; O'Neil B
J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Das S; Allen A; Berlin J
Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081
[TBL] [Abstract][Full Text] [Related]
3. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
5. Targeting cholangiocarcinoma.
Mertens JC; Ilyas SI; Gores GJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
[TBL] [Abstract][Full Text] [Related]
6. Is it Possible to Increase Survival of Patients with Intrahepatic Cholangiocarcinoma? A Case Report.
Oguz S; Kucukaslan H; Topaloglu S; Ones T; Baltacioglu F; Cobanoglu U; Calik A
J Gastrointest Cancer; 2021 Mar; 52(1):342-346. PubMed ID: 32617830
[No Abstract] [Full Text] [Related]
7. Paradigm shift from palliation to cure in metastatic microsatellite high colorectal carcinoma with immune checkpoint inhibitors.
Dhamani AM; Sheth HS; Bhattacharyya S; Shaikh IN
J Cancer Res Ther; 2021; 17(6):1552-1555. PubMed ID: 34916394
[TBL] [Abstract][Full Text] [Related]
8. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
9. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
10. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
12. Liver Inflammation and Hepatobiliary Cancers.
Leone V; Ali A; Weber A; Tschaharganeh DF; Heikenwalder M
Trends Cancer; 2021 Jul; 7(7):606-623. PubMed ID: 33674229
[TBL] [Abstract][Full Text] [Related]
13. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
Mou H; Yu L; Liao Q; Hou X; Wu Y; Cui Q; Yan N; Ma R; Wang L; Yao M; Wang K
BMC Cancer; 2018 Nov; 18(1):1105. PubMed ID: 30419854
[TBL] [Abstract][Full Text] [Related]
14. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Ma L; Hernandez MO; Zhao Y; Mehta M; Tran B; Kelly M; Rae Z; Hernandez JM; Davis JL; Martin SP; Kleiner DE; Hewitt SM; Ylaya K; Wood BJ; Greten TF; Wang XW
Cancer Cell; 2019 Oct; 36(4):418-430.e6. PubMed ID: 31588021
[TBL] [Abstract][Full Text] [Related]
15. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
[TBL] [Abstract][Full Text] [Related]
16. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
Sui M; Li Y; Wang H; Luo Y; Wan T; Wang X; Hu B; Cheng Y; Lv X; Xin X; Xu Q; Wang G; Lu S
J Immunother Cancer; 2019 May; 7(1):125. PubMed ID: 31064408
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival after multimodal therapy in a patient demonstrating intrahepatic cholangiocarcinoma with hilar invasion and intrahepatic metastases.
Morinaga S; Yamamoto Y; Sugano N; Wada H; Shiozawa M; Akaike M; Sugimasa Y
Int J Clin Oncol; 2008 Aug; 13(4):361-4. PubMed ID: 18704639
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
Front Immunol; 2021; 12():744571. PubMed ID: 34603331
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period.
Yamazaki S; Kubota K; Shimizu A; Notake T; Umemura K; Kamachi A; Goto T; Tomida H; Yamashita N; Sato M; Kanno H; Soejima Y
Intern Med; 2024 Apr; 63(8):1105-1112. PubMed ID: 37779076
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]